Gruppo Morandi





Twitter: @andMORand


Andrea Morandi is Associate Professor of Biochemistry at the University of Florence. He studied Biotechnology (BSc) and Medical Biotechnology (MSc) at the University of Florence and gained BSc in 2004 and MSc in 2006 both with honors, after a period of research on MAPK signaling in liquid and solid cancers.


Immediately after the MSc, Andrea started a PhD on the role of Tyrosine Kinase Receptors in breast cancer. In 2007, he moved to the Institute of Cancer Research in London in the laboratory of Prof Clare Isacke where he investigated, first as visiting PhD student and then as Worldwide Cancer Research supported postdoctoral fellow, the role of the tyrosine kinase receptor RET in response and resistance to endocrine therapy in breast cancer. In 2013, Andrea was awarded a Fondazione Italiana per la Ricerca sul Cancro Fellowship and returned to Florence. In 2018 became Faculty at the University of Florence.

 Member of the following Boards

 Member of editorial board of the following Journals

Editorial Board - Scientific Reports; 2017-

Associate Editor - BMC Cancer; 2017-

Associate Editor - Hormones and Cancer; 2017-

Associate Editor in Molecular and Cellular Oncology - Frontiers; 2019-

Guest Associate Editor in Cancer Metabolism - Frontiers; 2019-

Editorial Board - MDPI - Cancers; 2020-

Editorial Board - Taylor & Francis Online - Molecular and Cellular Oncology; 2020-


Research Team



I obtained my BSc and MSs in Biotechnology and Medical Biotechnology from the University of Florence and a PhD in Life Sciences and Biotechnologies at the University of Sassari. I investigated the role of metabolic reprogramming in endocrine therapy resistance since my PhD and I continued this journey thanks to Pezcoller Foundation and AIRC support. I am now an Assistant Professor in Biochemistry.



I received my BSc and MSc in Biotechnology and Medical and Pharmaceutical Biotechnology with honors from the University of Florence. I then moved in the laboratory of Prof Culig at the University of Innsbruck before starting a PhD in Biochemistry and Molecular Biology at University of Siena, investigating the role of metabolism in the response and resistance to CDK4/6 inhibitors. At present, I am a Fondazione Italiana per la Ricerca sul Cancro postdoctoral fellow in the Tumor Biochemistry Team.



I received my BSc and MSc with honors from the University of Florence. I then started a PhD in Biochemistry and Molecular Biology at the Oncohematology Lab of the Pediatric Oncology Hospital "Meyer". I am now a postdoctoral fellow supported by the Fondazione Annastaccatolisa working on the role of metabolic reprogramming in triple negative breast cancer



I obtained my BSc and MSc in Medical and Pharmaceutical Biotechnology from the University of Florence, both with honors, working on metabolic reprogramming in breast cancer.

I am now a PhD student in Biomedical Science at the University of Florence investigating the role of metabolic aberration and gender-related differences in the progression of non-alcoholic fatty liver disease to hepatocarcinoma.



I obtained my BSc and MSc in Medical Biotechnology from the University of Florence, both with honors. I then moved to Cologne (CECAD) in the laboratory of Dr Peltzer working on the interaction between lung cancer cells and adipocytes.

I am now a PhD student in Biomedical Science at the University of Florence investigating the role of estrogen in the preneoplastic lesions of the endometrium.

Current research interest

Metabolic reprogramming and deregulation are hallmarks of cancer. These alterations are not exclusively secondary effects of increased energetic and anabolic demands of the proliferating or invasive tumor cells. Instead, these traits alone are able to support and drive tumor initiation and progression. Importantly, metabolic reprogramming has a fundamental role in response and adaptation to anti-cancer therapies.

Our laboratory seeks to understand the contribution of metabolic reprogramming and the molecular mechanisms that drive this deregulation, particularly in the context of anti-cancer therapy resistance.

Indeed, preventing or bypassing drug resistance is arguably the most important unmet medical need in cancer management. Therefore, the identification of biomarker-defined patient populations that will most likely respond to the drugs is essential. Our work has multiple implications: (i) it will provide mechanistic insights involved in therapy response and resistance; (ii) it will apply multi-omics analysis to pre-clinical models to identify bio-markers of therapy response and resistance; (iii) it will generate experimental cellular models to study therapy response and resistance in several solid cancers.

Research Projects:

1. Metabolic reprogramming in endocrine therapy response and resistance in breast cancer

2. Metabolic reprograming in triple negative breast cancer

3. Metabolic determinants of CDK4/6 inhibitors resistance in breast cancer

4. Characterization of NAFLD to HCC progression: a gender approach with a focus on estrogen

5. The role of estrogen signalling in the progression of preneoplastic lesion of the endometrium

 Key words


Current sources of funding of Andrea Morandi

AIRC IG 2020-2024 – Principal Investigator  

Gender Medicine 2020-2021 - Principal Investigator

Pezcoller Foundation-SIC 2021 – Scientific Supervisor/Host of Dr Bacci

AIRC 2022 fellowship – Scientific Supervisor/Host of Dr Lorito

Annastaccatolisa 2022 fellowship - Scientific Supervisor/Host of Dr Subbiani

AIRC – Fondazione CR Firenze 2016-2020 – Group Leader

Fondi di Ateneo (ex 60%)

 Selected publications

1. De Santis MC, Gozzelino L, Margaria JP, Costamagna A, Ratto E, Gulluni F, Di Gregorio E, Mina E, Lorito N, Bacci M, Lattanzio R, Sala G, Cappello P, Novelli F, Giovannetti E, Vicentini C, Andreani S, Delfino P, Corbo V, Scarpa A, Porporato PE, Morandi A, Hirsch E, Martini M. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Gut. 2023 Feb;72(2):360-371. doi: 10.1136/gutjnl-2021-325117.

2. Meattini I, Livi L, Lorito N, Becherini C, Bacci M, Visani L, Fozza A, Belgioia L, Loi M, Mangoni M, Lambertini M, Morandi A. Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. Cancer Treat Rev. 2022 Jul;108:102417. doi: 10.1016/j.ctrv.2022.102417.

3. Bacci M*, Lorito N*, Smiriglia A, Morandi A.  Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance. Trends Can. 2020 Dec. Review. *co-first authors

4. Kowalik MA, Puliga E, Cabras L, Sulas P, Petrelli A, Perra A, Ledda-Columbano GM, Morandi A, Merlin S, Orrù C, Sanchez-Martin C, Fornari F, Gramantieri L, Parri M, Rasola A, Bellomo SE, Sebastian C, Follenzi A, Giordano S, Columbano A. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. J Hepatol. 2020 Jun;72(6):1159-1169. doi: 10.1016/j.jhep.2019.12.018.  

5. Lorito N*, Bacci M*, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M, Migliaccio I, Malorni L, Chiarugi P, Morandi A. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib. Cells. 2020 Mar 10;9(3). doi: 10.3390/cells9030668. (IF2020: 6.600) *co-first authors

6. Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, Mazzone M, Chiarugi P, Morandi A. Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. Cell Rep. 2019 Jul 2;28(1):104-118.e8. doi:10.1016/j.celrep.2019.06.010. 

  7. Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3.

    8. Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget. 2016 Dec 6;7(49):80543-80553. doi: 10.18632/oncotarget.11826.

  9. Kowalik MA*, Guzzo G*, Morandi A*, Perra A, Menegon S, Masgras I, Trevisan E, Angioni MM, Fornari F, Quagliata L, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Chiarugi P, Rasola A, Columbano A. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. Oncotarget. 2016 May 31;7(22):32375-93. doi: 10.18632/oncotarget.8632. *co-first authors

10. Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, Chiarugi P, Morandi A. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. Cancer Res. 2016 Mar 15;76(6):1615-26. doi: 10.1158/0008-5472.CAN-15-2038.

Full Publication list:










Ultimo aggiornamento



I cookie di questo sito servono al suo corretto funzionamento e non raccolgono alcuna tua informazione personale. Se navighi su di esso accetti la loro presenza.  Maggiori informazioni